Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Virtual reality offers new hope for chronic back pain sufferers

NCT ID NCT07033195

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This study tests two types of virtual reality therapy to see if they can reduce pain and improve daily function in people with chronic low back pain. Two hundred adults aged 18 to 85 with back pain lasting at least 6 months will use VR headsets for 8 weeks. Researchers will track changes in pain intensity, interference with daily life, and disability over 32 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women aged 18 to 85. * Self-reported diagnosis of chronic low back pain without radicular symptoms. * Chronic low back pain duration of 6 months or more, and pain at least half the days in the last 6 months. * Lower back pain as primary chronic pain complaint (greater than pain in other bodily regions). * Average pain intensity of 4 or more out of 10 for the past week (from BPI-SF). * English fluency (8th grade level). * Willing to comply with study procedures/restrictions. * Access to Wi-Fi. * Implicit de facto internet and computer literacy. Exclusion Criteria: * Applicants, who are pregnant, planning pregnancy, or breastfeeding * Back pain associated with compensation / litigation within 1 year. * Leg pain greater than back pain (suggests neuropathic pain; may be less responsive to psychological therapy). * Chronic pain other than chronic back pain. * Diagnoses of schizophrenia, multiple personality dissociative identity disorder. * History of major depressive disorder not controlled with medication or other conditions that produce significant cognitive or emotional disability. * History of substance abuse. * Inability to undergo MRI (determined at screening; see XVI: Risks to Participants). * Any clinically significant unstable medical abnormality or acute or chronic disease of cardiovascular, gastrointestinal, respiratory (e.g., chronic obstructive pulmonary disease), hepatic, or renal systems; including: history of cardiovascular disease or issues (e.g., recent heart attack), stroke; brain surgery, or brain tumor; Diabetes; cancer (last 12 months); diagnosis of a specific inflammatory disorder: rheumatoid arthritis, polymyalgia rheumatica, scleroderma, Lupus; polymyositis; or Cauda Equina syndrome. * History of seizure disorder, epilepsy, convulsions, or increased intracranial pressure anytime except pediatric febrile seizures. * History of vertigo, dizziness, susceptibility to motion sickness * History of head injury within 6 months, * Unexplained, unintended weight loss of 'â• 20 lbs in past year. Self-reported history of (digital) eye strain or computer vision syndrome. Unable or unwilling to meet study attendance requirements. MRI contraindications as determined by MRI safety screen (e.g., pregnancy, metal in body, claustrophobia, using the standard screen conducted by the MRI imaging facility).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic back pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Back Pain Chronic Pain chronic pain syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Colorado Boulder

    Boulder, Colorado, 80309, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.